28th Nov - Drug action at ion channels Flashcards

1
Q

Describe the structure of Kir6

A

2 TM domains in each subunit
2 Kir6 subunits form the pore forming domain of KATP channels
Kir6 has an ATP binding site
Kir6 are not voltage sensitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is Kir6?

A

An inwardly rectifying potassium channel which form the pore forming subunits of Katp channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Molecularly what causes inward rectifying currents in an inward rectifying potassium channel?

A

Cytoplasmic long chain aliphatic compounds with more than one amine group are attracted the intracellular side of the channel, blocking the channel creating the characteristic I/V curve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the function of the sulphonylurea receptor subunits?

A

They are the regulatory subunits of Katp which bind sulphonylureas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Give an example of a sulphonylurea

A

glibenclamide

tolbutamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What binds to the sulphonylurea receptor subunits of the Katp channel?

A

Sulfonylureas

Meglinitides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Outline the role of Katp channels in insulin secretion

A

Low metabolism –> Increase in MgADP and Decrease in ATP –> Katp channels open and calcium channels close –> hyperpolarisation

High glucose –> high metabolism –> Increase in atp and decrease in MgADP –> Katp channels close and potassium channels open –> depolarisation –> insulin release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do sulfonylureas stimulate insulin release?

A

They inhibit the Katp channel causing depolarisation and insulin release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the sulfonylurea drug of choice?

A

Tolbutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is permanent neonatal diabetes mellitus?

A

Diabetes diagnosed int he first 6 months of life that does not resolve over time caused by a mutation in KCNJ11 (Kir 6.2) or ABCC8 (Sur1) mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the two different mutations in KCNJ11 in permanent neonatal diabetes mellitus and what are their clinical effects?

A

Mild disease = R201H/C mutation in the ATP binding site

  • Reduces ATP sensitivity of the Katp channel
  • Causes the channel to favour the open state leading to a reduction in insulin release
  • Will respond to sulfonylureas

Severe disease = V59G/M, Q52R mutation in the gating region

  • Increases the open probability independent of ATP
  • Causes hyperpolarisation of the cell
  • Not treatable with sulphonylureas
  • Also causes developmental delay epilepsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the effects of a mutation in SUR1 in permanent neonatal diabetes mellitus?

A

Overactive channels
Mutant channel does not does in response to high ATP
Sulphonylureas are not always effective, individual molecular diagnosis is required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is hyperinsulinemic hypoglycemia of infancy?

A

Congenital hyperinsulinism

Kir 6.2 mutations and Sur1 mutations cause loss of Katp channel function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the two classes of hyperinsulinemic hypoglycemia?

A

Class 1

  • Protein trafficking deficit
  • Protein not present at the membrane
  • very severe

Class 2

  • Functional mutation, usually of SUR1
  • Channels remain closed
  • Mild
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the clinical use of drugs targeted to open Katp channels in the vascular smooth muscle?

A

To treat hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Give an example of an antihypertensive that targets Katp channels

A

Diazoxide
Minoxidil
Nicorandil

17
Q

Describe the effects of the anti-hypertensive diazoxide

A

Targets pancreatic Beta cell katp channels and smooth muscle Katp channels

Side effects: Hyperglycaemia, beard growth (hirsutism), general bodily hair growth (hypertrichosis)

18
Q

Describe the effects of the anti-hypertensive minoxidil

A

Selectively targets smooth muscle

Side effects: Hirsutism, hypertrichosis and cardiac problems

19
Q

Describe the effects of the anti-hypertensive nicorandil

A

Selectively targets smooth muscle Katp channels
Also promotes nitrovasodilation

Side effects: GI ulceration

20
Q

Name a drug that targets Katp channels that can be used to treat alopecia

A

Minoxidil

21
Q

How was the high affinity binding site for tolbutamide identified to be the SUR1 subunit of the KATP channel by Ashcroft in 1999?

A

Made chimeras between SUR1 and SUR2A to identify the region involved in high affinity tolbutamide block
Replacing TM 14-16 of SUR2A w/ SUR1 –> inhibition
Replacing TM 13-16 of SUR1 w/SUR2A –> abolished inhibition
Mutating S1237Y –> abolished inhibition

–> Suggest site in COOH terminal set of TMs of SUR1 residues